Company Overview and News
Transportation stocks seem to be back on track in 2018, resulting from two factors. The first factor is the passage of the Tax Cuts and Jobs Act. The provision of deduction capital expenditures for tax calculation purposes in the year incurred has favored transportation (XTN) stocks—specifically the railroads.
On May 10, Western US rail freight giant Union Pacific (UNP) declared a quarterly cash dividend of $0.73 per share on its common stock. In the first quarter, UNP raised its quarterly cash dividend from $0.665 per share to $0.73 per share. The company’s quarterly cash dividend on equity shares is payable on June 29 to stockholders of record on May 31.
Genesee & Wyoming (GWR) is the largest short line carrier in the US and Canada with operations in the US, Canada, UK/Europe, and parts of Australia. Though it’s not a Class I railroad, it is often compared with US Class I railroads.
So far this year, Western US rail freight giant Union Pacific’s (UNP) YoY (year-over-year) freight volume growth has lagged behind rival BNSF Railway’s (BRK.B). In Week 18, UNP’s carload traffic rose 5.2% YoY (year-over-year) to ~94,400 carloads (excluding intermodal units) from ~89,800. It underperformed BNSF Railway (BRK.B), whose carload traffic grew 10.7%, and US railroads.
In the week ended May 5, Berkshire Hathaway–owned BNSF Railway’s (BRK.B) carload volumes grew by double digits, by 10.7% YoY (year-over-year) to ~98,100 railcars from ~88,600, doubling the growth seen by competitor Union Pacific (UNP). The latter’s carloads grew 5.2% in Week 18, while US rail carriers’ (IYT) grew 6.4%.
A busy home schedule has limited my time dedicated to the stock market, but my dividend growth portfolio continues to perform without me.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Philip Morris (PM), ConocoPhillips (COP) and Alibaba (BABA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Schwab (SCHW), NextEra (NEE) and MetLife (MET). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Berkshire Hathaway’s (BRK.B) BNSF Railway has managed high growth in recent quarters, with improved margins and operating efficiency. In 1Q18, BNSF’s revenue grew 8.5% YoY (year-over-year) to $5.6 billion, helped by a 5.1% increase in volumes and a 1.8% increase in average revenue per unit. Pricing was impacted by higher fuel prices (USO) and surcharges. Berkshire expects a modest volume increase in the remainder of 2018.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Caterpillar (CAT) and General Motors (GM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Sears teams with Amazon to provide tire installation for any brand of tires bought on Amazon.com
The inland barge market seems to be bottoming/turning, as spot rates are rising and Kirby's utilization is improving.
Berkshire Hathaway–owned BNSF Railway’s (BRK.B) carload traffic grew 4.8% YoY (year-over-year) to ~98,000 railcars from ~93,500 in the week ended April 29, or Week 17 of 2017. In comparison, competitor Union Pacific’s (UNP) carload traffic expanded 4.3% YoY. BNSF’s carload volume increase, percentage-wise, was 1.1% more than US railroads’ (IYT) 3.7% gains in the same category in Week 17.
12m - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
as of ET